Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 7 of 15

 
 

Revolution Medicines (NASDAQ:RVMD)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$61.00 (10.6% Upside)

About Revolution Medicines

Revolution Medicines logoRevolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/7/2024HC WainwrightBoost Price TargetBuy ➝ Buy$62.00 ➝ $64.00
11/7/2024Needham & Company LLCBoost Price TargetBuy ➝ Buy$61.00 ➝ $68.00
11/7/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$54.00 ➝ $63.00
11/7/2024Piper SandlerBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $70.00
10/28/2024GuggenheimBoost Price TargetBuy ➝ Buy$72.00 ➝ $82.00
10/28/2024OppenheimerBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $60.00
10/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00 ➝ $61.00
10/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00 ➝ $61.00
9/27/2024BarclaysBoost Price TargetOverweight ➝ Overweight$54.00 ➝ $60.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$56.00 ➝ $56.00
 

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

Click Here For Your Free Guide